Report period | 2018 | 2019 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
End date of the reporting period | |||||
Capitalization, CN¥ | |||||
Capitalization, $ | |||||
Enterprise Value | |||||
Book Value | |||||
Shareholders Book Value | |||||
Current liabilities | |||||
Noncurrent liabilities | |||||
Total liabilities | |||||
Debt | |||||
Cash and cash equivalents | |||||
Net debt | |||||
Assets | |||||
Total ordinary shares | |||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
1801:HK | Innovent Biologics | Common share | - | KYG4818G1010 | HK$33 |
Company name | Innovent Biologics |
---|---|
Tags | #hong_kong_spb |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | 168 Dongping Street Suzhou Industrial Park Suzhou 215123 China |
Mailing address | 168 Dongping Street Suzhou Industrial Park Suzhou 215123 China |
Website | www.innoventbio.com |